Needham Reiterates Buy on Autolus Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum reiterates a Buy rating on Autolus Therapeutics (NASDAQ:AUTL) and maintains a $7 price target.
June 05, 2023 | 9:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Autolus Therapeutics and maintains a $7 price target.
The news directly mentions Autolus Therapeutics (NASDAQ:AUTL) and the Buy rating reiteration by Needham analyst Gil Blum, along with the maintained $7 price target. This reaffirmation of a positive outlook on the stock is likely to have a positive short-term impact on its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100